SLFN11 informs on standard of care and novel treatments in a wide range of cancer models

SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy

(2020) Vincenza Conteduca et al.   MOLECULAR CANCER THERAPEUTICS

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

(2020) Florence Coussy et al.   Science Translational Medicine

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress

(2020) Junko Murai et al.   Cell Reports

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

(2020) Panagiotis A Konstantinopoulos et al.   LANCET ONCOLOGY

Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress

(2019) Lucy A. Young et al.   CANCER RESEARCH

Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies

(2019) Junko Murai et al.   PHARMACOLOGY & THERAPEUTICS

Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines

(2019) JUNYA IWASAKI et al.   ANTICANCER RESEARCH

Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy

(2019) Kevin Shee et al.   PLoS One

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

(2019) Jacqueline H. L. Fok et al.   Nature Communications

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

(2018) C Cruz et al.   ANNALS OF ONCOLOGY

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2′,2′-difluorodeoxyuridine and their nucleotides

(2018) Ellen J. B. Derissen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11)Expression with Class I Histone Deacetylase Inhibitors

(2018) Sai-Wen Tang et al.   CLINICAL CANCER RESEARCH

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

(2018) M. Catherine Pietanza et al.   JOURNAL OF CLINICAL ONCOLOGY

The ATR Inhibitor AZD6738 Synergizes with GemcitabineIn VitroandIn Vivoto Induce Pancreatic Ductal Adenocarcinoma Regression

(2018) Yann Wallez et al.   MOLECULAR CANCER THERAPEUTICS

SLFN11 Blocks Stressed Replication Forks Independently of ATR

(2018) Junko Murai et al.   MOLECULAR CELL

Targeting the replication stress response in cancer

(2018) Josep V. Forment et al.   PHARMACOLOGY & THERAPEUTICS

Abstract CT118: PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor)

(2018) Alienor Berges et al.   CANCER RESEARCH

pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry

(2018) Gemma N. Jones et al.   BRITISH JOURNAL OF CANCER

Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models

(2018) Caitlin D Lowery et al.   CLINICAL CANCER RESEARCH

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent

(2018) Kevin M. Foote et al.   JOURNAL OF MEDICINAL CHEMISTRY

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

(2018) Todd A. Hopkins et al.   MOLECULAR CANCER RESEARCH

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer

(2017) Alberto Ballestrero et al.   Journal of Translational Medicine

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

(2017) C. Allison Stewart et al.   Oncotarget

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

(2016) Benjamin H. Lok et al.   CLINICAL CANCER RESEARCH

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

(2016) Suzanne Leijen et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

(2016) Junko Murai et al.   Oncotarget

High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment

(2015) Yanhong Deng et al.   BMC CANCER

SLFN11 inhibits checkpoint maintenance and homologous recombination repair

(2015) Y. Mu et al.   EMBO REPORTS

Targeting the DNA Damage Response in Cancer

(2015) Mark J. O’Connor   MOLECULAR CELL

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

(2015) Vanesa Nogales et al.   Oncotarget

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents

(2012) G. Zoppoli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with 19F NMR spectroscopy

(2011) Tashinga E. Bapiro et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS